Valuation: Iqvia Holdings

Market Cap 34.38B 30.11B 27.73B 25.74B 48.88B 3,279B 49.54B 332B 129B 1,610B 129B 126B 5,581B P/E 2026 *
25.1x
P/E 2027 * 20.8x
Enterprise Value 48.04B 42.07B 38.75B 35.97B 68.3B 4,582B 69.23B 464B 181B 2,249B 180B 176B 7,799B EV / Sales 2026 *
2.78x
EV / Sales 2027 * 2.58x
Free-Float
63.6%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 64 2016-10-02
Director of Finance/CFO 51 2026-02-27
Chief Tech/Sci/R&D Officer - 2025-12-31
Director TitleAgeSince
Director/Board Member 68 2015-02-04
Chairman 64 2016-10-02
Director/Board Member 69 2016-10-02
Change 5-day change 1-year change 3-year change Capi.($)
+1.04%+2.60% - - 34.38B
-0.26%+6.16%+3.84%+10.36% 50.25B
+0.40%-1.37%+401.69%+625.15% 40.39B
+3.97%+6.71%+26.06%+63.36% 34.4B
-4.19%-1.84%+3.76%+32.17% 26.32B
-2.40%+1.60% - - 16.64B
+1.34%+5.68%+75.77%+141.51% 16.14B
+1.75%+1.95%+15.96%+23.19% 13.71B
+1.69%+3.09%+93.44%+99.19% 13.75B
-2.79%+8.48%+1,742.65%+688.05% 12.69B
Average +0.05%+8.92%+295.39%+210.37% 24.92B
Weighted average by Cap. +0.23%+6.51%+203.46%+199.82%

Financials

2026 *2027 *
Net sales 17.29B 15.14B 13.94B 12.94B 24.58B 1,649B 24.91B 167B 64.96B 809B 64.92B 63.49B 2,806B 18.28B 16.01B 14.75B 13.69B 26B 1,744B 26.35B 177B 68.7B 856B 68.66B 67.15B 2,968B
Net income 1.39B 1.21B 1.12B 1.04B 1.97B 132B 2B 13.4B 5.21B 64.96B 5.21B 5.1B 225B 1.63B 1.42B 1.31B 1.22B 2.31B 155B 2.34B 15.7B 6.11B 76.14B 6.11B 5.97B 264B
Net Debt 13.66B 11.97B 11.02B 10.23B 19.43B 1,303B 19.69B 132B 51.34B 640B 51.31B 50.18B 2,218B 12.84B 11.24B 10.36B 9.61B 18.25B 1,225B 18.5B 124B 48.25B 601B 48.21B 47.16B 2,084B
Logo Iqvia Holdings
Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows: - development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes; - development of technology and analytics solutions (40.6%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers; - integrated services (4.9%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc. Net sales are distributed geographically as follows: Americas (47.5%), Europe and Africa (31.8%) and Asia/Pacific (20.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-